Search results for "Type 2"

showing 10 items of 1034 documents

Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

2021

Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to cardiovascular risk reduction in patients with type 2 diabetes (T2D). However, their underlying molecular mechanisms remain unclear. This study aimed to evaluate the effects of empagliflozin, a novel potent and selective iSGLT-2, on anthropometric and endocrine parameters, leukocyte–endothelium interactions, adhesion molecules, ROS production, and NFkB-p65 transcription factor expression. According to standard clinical protocols, sixteen T2D patients receiving 10 mg/day of empagliflozin were followed-up for 24 weeks. Anthropometric and analytical measurements were performed at baseline, 12 weeks, and 24 weeks. Interacti…

Mitochondrial ROScardiovascular riskGPX1medicine.medical_specialtyEndotheliumPhysiologyClinical Biochemistryempagliflozin030209 endocrinology & metabolismLeukocyte RollingInflammationRM1-950030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineEmpagliflozinmedicineoxidative stressMolecular Biologybusiness.industryCell adhesion moleculeCommunicationCell Biologymedicine.anatomical_structureEndocrinologyinflammationtype 2 diabetesTherapeutics. Pharmacologymedicine.symptombusinessOxidative stressAntioxidants
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct

Long Daytime Napping Is Associated with Increased Adiposity and Type 2 Diabetes in an Elderly Population with Metabolic Syndrome

2019

Research examining associations between objectively measured napping time and type 2 diabetes (T2D) is lacking. This study aimed to evaluate daytime napping in relation to T2D and adiposity measures in elderly individuals from the Mediterranean region. A cross-sectional analysis of baseline data from 2190 elderly participants with overweight/obesity and metabolic syndrome, in the PREDIMED-Plus trial, was carried out. Accelerometer-derived napping was measured. Prevalence ratios (PR) and 95% confidence intervals (CI) for T2D were obtained using multivariable-adjusted Cox regression with constant time. Linear regression models were fitted to examine associations of napping with body mass inde…

Napfungimental disordersnutritional and metabolic diseasesWaist circumferenceType 2 diabetesPREDIMED-Plushuman activitiesActigraphypsychological phenomena and processesBody mass index
researchProduct

An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System

2020

The prevalence of diabetes mellitus (DM) rises constantly each year worldwide. Because of that, the funds allocated for the DM treatment have increased over time. Regarding the number of DM cases, Romania is among the top ten countries in Europe. Based on the National Diabetes Programme (NDP), antidiabetic drugs and other expenditures (Self-monitoring blood glucose (SMBG) test, HbA1c, insulin pumps/insulin pumps supplies) are free of charge. This programme has undergone many changes in drugs supply, in the last two decades: re-organizing the NDP, authorization of new molecules with high prices (e.g., SGLT-2 inhibitors, etc.) or new devices (e.g., insulin pumps, etc.) The main purpose of thi…

National Health Programsefficiency indicatorsHealth Toxicology and Mutagenesismedicine.medical_treatmentExploratory researchlcsh:Medicinediabetes mellitus costantidiabetic drugs030209 endocrinology & metabolismArticleNational Diabetes Programme03 medical and health sciencesPharmacoeconomics0302 clinical medicineCost of IllnesspharmacoeconomicsInflation rateDiabetes mellitusHumansMedicine030212 general & internal medicinephysical indicatorsRetrospective StudiesRomaniabusiness.industryOptimal treatmentInsulinlcsh:RPublic Health Environmental and Occupational Healthmedicine.diseaseEuropeDiabetes Mellitus Type 2National health insuranceRomanian National Health Insurance SystemDiabetic patientbusinessDemographyInternational Journal of Environmental Research and Public Health
researchProduct

Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency.

2007

<i>Background/Aim:</i> Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established. The aim of this study was to evaluate whether onset, severity, and prevalence of anaemia during the course of CKD is different between type 2 diabetic and non-diabetic patients. <i>Methods:</i> We enrolled 281 patients with: (1) type 2 diabetes and no CKD (n = 75); (2) type 2 diabetes plus CKD (n = 106), and (3) CKD without type 2 diabetes (n = 100). According to K/DOQI guidelines, the patients with renal insufficiency (i.e., those with a glomerular filtration rate <60 ml/min) were subgr…

NephrologyMaleglomerulus filtration rateType 2 diabetesurologic and male genital diseasesGastroenterologySeverity of Illness Indexadult; aged; anemia; article; chronic kidney failure; comparative study; controlled study; creatinine clearance; diabetic nephropathy; disease course; disease severity; female; glomerulus filtration rate; hemoglobin blood level; human; kidney failure; kidney function; major clinical study; male; non insulin dependent diabetes mellitus; practice guideline; prevalence; priority journal; risk assessment; Aged; Anemia; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Kidney Failure Chronic; Male; Middle Aged; Prevalence; Severity of Illness Index; Sex DistributionKidney FailureDiabetic nephropathychemistry.chemical_compoundHemoglobinsChronic kidney diseasecreatinine clearancePrevalenceDiabetic NephropathiesChronickidney functioncomparative studynon insulin dependent diabetes mellitusadultdisease coursearticlerisk assessmentAnemiaGeneral Medicinechronic kidney failureMiddle Agedpriority journalNephrologyCreatininedisease severityFemaleType 2Glomerular Filtration Ratemedicine.medical_specialtyAnaemia diabetes mellitus; Chronic kidney disease diabetes mellitus; Type 2 diabetes mellitus anaemiaRenal functionAnaemiaDiabetes mellitusInternal medicineType 2 diabetes mellitusDiabetes MellitusmedicineHumanscontrolled studyhumanSex DistributionAgedSettore MED/14 - NefrologiaCreatininehemoglobin blood levelbusiness.industrydiabetic nephropathypractice guidelineType 2 Diabetes Mellitusmedicine.diseasemajor clinical studySurgerychemistryDiabetes Mellitus Type 2Kidney Failure ChronicbusinessKidney disease
researchProduct

Neurobiology of cannabinoid receptor signaling
.

2020

The endocannabinoid system (ECS) is a highly versatile signaling system within the nervous system. Despite its widespread localization, its functions within the context of distinct neural processes are very well discernable and specific. This is remarkable, and the question remains as to how such specificity is achieved. One key player in the ECS is the cannabinoid type 1 receptor (CBEl sistema endocannabinoide (SEC) apareció como un sistema de señalización muy versátil en el sistema nervioso. A pesar de su existencia amplia y ubicua, sus funciones están integradas en el contexto de distintos procesos neuronales y, en última instancia, son bastante bien discernibles y específicas. Esto es n…

Nervous systemCannabinoid receptormedicine.medical_treatment2-ArachidonoylglycerolContext (language use)BiologyReceptor Cannabinoid CB203 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeurobiologyReceptor Cannabinoid CB1Cannabinoid receptor type 2medicineAnimalsHumansanandamideReceptorReceptors Cannabinoidbehaviorcannabinoid receptorEndocannabinoid systemState of the Art030227 psychiatry2-arachidonoylglycerolmedicine.anatomical_structurechemistryneural communicationCannabinoidNeuroscienceEndocannabinoidsSignal TransductionDialogues in clinical neuroscience
researchProduct

Increased Arterial Augmentation and Augmentation Index as Surrogate Parameters for Arteriosclerosis in Subjects with Diabetes Mellitus and Nondiabeti…

2007

Background: Arterial augmentation (AP) and the augmentation index (Aix) are surrogate parameters of arterial stiffness and are commonly used as predictors for cardiovascular risk. The aim of this study is to compare these parameters in diabetic subjects and nondiabetic cardiovascular risk subjects with healthy control subjects. Methods: One hundred sixty-six nonsmoking subjects aged between 35 and 70 years were included in the study, which included 100 subjects with cardiovascular disease but not diabetes (mean age 62.73±8.75 years), 33 subjects with type 2 diabetes (66.58±2.69 years), and 33 healthy controls (51.89±8.91 years). In these subjects, arterial stiffness was measured by the diff…

Neurological and Microvascular Functionmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismBiomedical EngineeringCentral pressure030209 endocrinology & metabolismBioengineeringMean ageArteriosclerosisDiseaseType 2 diabetesmedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineHealthy controlInternal MedicinemedicineArterial stiffnessCardiology030212 general & internal medicinebusinessJournal of Diabetes Science and Technology
researchProduct

Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome.

2012

Abstract Aim To evaluate the concentration of metabolites (NO2−, NO3−) of nitric oxide (NO) in metabolic syndrome (MS). Materials and methods We enrolled 106 subjects (45 women and 61 men) with MS of which 43 (14 women and 27 men) with diabetes mellitus and 63 (31 women and 32 men) without diabetes mellitus, and 54 subjects (19 women and 35 men) as control group. The nitric oxide metabolites (nitrite + nitrate = NOx) were evaluated employing the Griess reagent. Results In the whole group of MS subjects was evident, in comparison with control group, a significant increase in NOx. The same finding was also present between control group and diabetic subjects with MS and between control group a…

Nitric oxide metaboliteinorganic chemicalsMalemedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedicine.disease_causeNitric OxideNitric oxidechemistry.chemical_compoundGriess testInternal medicineDiabetes mellitusInternal MedicinemedicineHumansNitritesInflammationMetabolic SyndromeNitratesbusiness.industryGeneral MedicineFastingAnthropometryMiddle AgedNitric oxide metabolismmedicine.diseaseOxidative StressBlood pressureEndocrinologychemistryDiabetes Mellitus Type 2Oxidative streFemaleMetabolic syndromebusinessOxidative stressBiomarkersDiabetesmetabolic syndrome
researchProduct

Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic.

2011

Nonalcoholic fatty liver (NAFL) and especially its inflammatory variant nonalcoholic steatohepatitis (NASH) have become a major challenge to healthcare systems worldwide because of the increasing prevalence of its major risk factors obesity and type 2 diabetes, which are closely linked to overeating, physical inactivity, and the metabolic syndrome.Between 10 and 20% of patients with NAFL develop NASH, which can progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The overall mortality in these patients is significantly increased because of both cardiovascular and liver-related complications. Sustained weight loss by diet and exercise, which is the most effective the…

Nonalcoholic steatohepatitisDiet ReducingEndocrinology Diabetes and MetabolismAnti-Inflammatory AgentsType 2 diabetesBioinformaticsBile Acids and SaltsNon-alcoholic Fatty Liver DiseaseGeneticsmedicineAnimalsHumansHypoglycemic AgentsObesityEpidemicsMolecular BiologyRandomized Controlled Trials as TopicNutrition and Dieteticsbusiness.industryFatty liverCell Biologymedicine.diseaseObesityFatty LiverHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessHealthcare systemCurrent opinion in lipidology
researchProduct